Lenacapavir Cost: US Access Barriers | Crofoot Commentary
- The promise of lenacapavir (Sunlenca; Gilead) as a highly effective tool for HIV prevention (PrEP) faces a significant hurdle: its cost.
- While lenacapavir boasts near 100% effectiveness in preventing HIV transmission, its annual cost, ranging from $40,000 to $42,000, presents a major financial barrier.
- Crofoot anticipates delays, noting that some insurers take up to 12 months to review new drugs.
The high cost of lenacapavir, a groundbreaking HIV prevention (PrEP) drug, is poised to limit its widespread use in the U.S.. This article, based on expert commentary, dissects the financial barriers, wiht annual costs reaching $40,000-$42,000, potentially hindering its rollout even with nearly 100% effectiveness. Insurance coverage hurdles and FDA approval pathways add more complexity,potentially slowing patient access,particularly for vulnerable groups. Dr. Gordon crofoot expresses concerns about affording lenacapavir for patients. News Directory 3 reports on the key accessibility issues. The twice-yearly injection’s advantages are clear, but the price poses challenges. Will advocacy efforts enable broader availability of this crucial HIV PrEP option? Discover what’s next…
High Cost limits Lenacapavir’s role as HIV Prevention (PrEP) in U.S.
Updated June 22, 2025
The promise of lenacapavir (Sunlenca; Gilead) as a highly effective tool for HIV prevention (PrEP) faces a significant hurdle: its cost. According to Dr. Gordon Crofoot, president and principal investigator at The Crofoot Research Center, the price tag could severely restrict access, particularly for vulnerable populations.
While lenacapavir boasts near 100% effectiveness in preventing HIV transmission, its annual cost, ranging from $40,000 to $42,000, presents a major financial barrier. This cost could impede rapid rollout,even after its approval June 19.
Insurance coverage is another concern. Crofoot anticipates delays, noting that some insurers take up to 12 months to review new drugs. He fears that even with its high efficacy, lenacapavir may not be promptly covered. The FDA’s approval pathway could further complicate matters,possibly requiring patients to first try and fail with Truvada (emtricitabine/tenofovir; Gilead) before lenacapavir is considered.
The financial barriers to accessing lenacapavir for HIV prep in the U.S. stand in stark contrast to other countries where its twice-yearly injection and ease of use could be readily adopted. Crofoot expressed concern about the challenges he anticipates as a provider in making this drug accessible to his patients.
I love the drug. I’ve loved the drug from the begining.I love the way it effectively works. I love that it’s easy to use,[is] long acting,[and] doesn’t have side effects,but it’s going to be hard for me to use this drug for PrEP initially,with the finances at $40,000 [to] $42,000 a year. that’s going to be the biggest problem to getting this drug going.
What’s next
Advocates and healthcare providers will likely focus on negotiating with insurance companies and exploring patient assistance programs to improve access to lenacapavir as HIV PrEP, particularly for those who need it most.